Skip to main content

Table 3 Univariate analysis of the risk factors for CSS (N = 57)

From: High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer

Variables Univariate analysis
HR (95% CI) p value Log-rank p
Age (< 60 vs. ≥ 60) 1.308 (0.292–5.855) 0.725 0.725
Gender (male vs. female) 1.657 (0.309–8.888) 0.555 0.551
AJCC/UICC stage    0.573
 I Reference 0.603  
 II 0.327 (0.02–5.240) 0.429  
 III 0.966 (0.110–8.457) 0.975  
Length (< 5 vs. ≥ 5 cm) 1.308 (0.292–5.855) 0.725 0.960
Histopathology    0.629
 Poorly differentiated Reference 0.641  
 Moderately differentiated 1.022 (0.105–9.920) 0.985  
 Undefined 2.089 (0.216–20.179) 0.524  
CEA levels (< 5 vs. ≥ 5 ng/ml) 1.483 (0.329–6.689) 0.608 0.606
Distance to the anal verge (< 5 vs. ≥ 5 cm) 0.432 (0.051–3.645) 0.441 0.428
Courses of radiotherapy (one course vs. two course) 1.075 (0.129–8.980) 0.946 0.946
Chemotherapy regime (Capecitabine vs. Capoex/folfox) 1.005 (0.195–5.187) 0.996 0.996
Cycles of chemotherapy (≤ 4 vs. > 4) 2.052 (0.241–17.441) 0.510 0.502
Response to treatment (cCR vs. non-cCR) 6.361 (1.380–29.328) 0.018 0.007*
Comorbidities (yes vs. no) 39.757 (0.033–48,411.962) 0.310 0.083
  1. CSS cancer specific survival, HR hazard ratio, AJCC/UICC American Joint Committee on Cancer/International Union Against Cancer, CEA carcinoembryonic antigen, cCR clinical complete response
  2. *Statistically significant